Mass Tort Lead Generation: Screening Criteria and Intake Readiness

Mass tort campaigns are high-stakes lead generation. A single qualified claimant can be worth a great deal to a firm, but the categories are defined by narrow eligibility windows, specific product or exposure requirements, and evolving litigation status. Buy leads without tight screening and you fund a call center full of people who do not qualify. Buy well but let intake lag, and qualified claimants sign with a competitor. Success in mass tort depends on two disciplines working together: precise screening criteria and intake readiness. This guide covers both, along with the documentation and compliance habits that keep a campaign defensible.

What Makes Mass Tort Leads Unique

Unlike a single-event personal injury claim, mass tort involves many claimants harmed by the same product, drug, or exposure. Each tort has its own eligibility rules: a specific medication, a date range of use, a diagnosed injury, or documented exposure. Those rules can shift as litigation develops, so a lead source and an intake team must stay current on the criteria for each active campaign.

Because the qualifying facts are specific, screening is more involved than in most lead categories. A claimant must often confirm product use, timing, diagnosis, and treatment before they are worth advancing. That makes upfront qualification the single biggest driver of return on spend.

Screening Criteria That Matter

Every mass tort campaign needs a written screening standard agreed between the buyer and the lead source. The exact questions vary by tort, but the framework is consistent.

Screening area	What to confirm
Product or exposure	Specific product, drug, or exposure named in the litigation
Timing	Use or exposure fell within the qualifying date range
Injury or diagnosis	Documented condition tied to the tort
Treatment	Medical care or records that support the claim
Prior representation	Claimant is not already represented for this matter
Jurisdiction	Location fits the applicable venue rules

Agree on which of these are hard disqualifiers and which are soft signals. A lead missing a hard criterion should never advance, no matter how motivated the claimant sounds.

Intake Readiness

Screening identifies a qualified claimant; intake converts them into a signed retainer. In mass tort, the gap between the two is where most value is lost. Claimants often respond to several firms, so the one that answers fast, explains the process clearly, and makes signing easy wins.

Intake readiness checklist

• Staff intake for the hours your leads and calls actually arrive.
• Use a script that confirms screening criteria before pitching representation.
• Have retainer agreements ready for immediate electronic signature.
• Capture and store supporting details and any documentation the claimant references.
• Set a follow-up cadence for claimants who need to gather records.
• Route qualified claimants to a licensed attorney or supervised intake specialist.

Speed and clarity matter as much here as in any category. A qualified claimant who waits a day for a callback is a claimant a competitor is already signing.

Coordinating marketing screening with legal review

Marketing qualification and a lawyer's case evaluation are not the same thing, and conflating them creates risk. Intake screening confirms that a claimant appears to meet the campaign's stated criteria; it does not decide whether the firm can or should represent them. Build a clear handoff so that qualified claimants move promptly from intake to a licensed attorney or a properly supervised evaluation, with the screening notes and any documentation attached. This division protects the claimant, keeps the firm within its professional obligations, and prevents an enthusiastic intake specialist from making representations they are not authorized to make. Document where marketing ends and legal review begins so the boundary is unmistakable.

Managing Cost and Quality

Mass tort leads are expensive, so quality control is not optional. Track your metrics from the first contact all the way to a signed and retained client.

• Contact rate: Are you reaching the claimants you buy?
• Qualified rate: How many meet the written screening criteria?
• Retainer rate: How many qualified claimants sign?
• Cost per signed retainer: The number that actually reflects campaign health.

Watch for red flags: leads that fail hard criteria at high rates, claimants already represented, or duplicate submissions. Address quality problems with your source promptly rather than absorbing the loss.

Duplicate and re-solicitation control

Because mass tort campaigns often run across many publishers and long time horizons, the same claimant can surface more than once. Duplicate submissions inflate spend and, worse, can mean a claimant is contacted repeatedly by the same firm, which erodes trust and invites complaints. Maintain a suppression and duplicate-detection process that spans every source you buy from, and match on the identifiers that matter for the tort. Agree with your sources on how duplicates are credited so you are not paying twice for a claimant you already have in intake.

Keeping current as litigation evolves

Mass tort eligibility is not static. Qualifying date ranges, named products, and accepted injuries change as litigation progresses, courts rule, and settlements form. A screening standard that was correct last quarter can silently start rejecting valid claimants or advancing ineligible ones. Assign someone to monitor each active tort's criteria and to update your intake script and your source's screening the moment the parameters shift. Treat the written screening standard as a living document, versioned and dated, so your team always works from the current requirements rather than an outdated copy.

Documentation and Compliance

Mass tort operates under both advertising regulation and state bar rules governing attorney marketing and client solicitation. Firms are responsible for their own compliance. Keep clear records of how each lead was generated, what the advertising claimed, and what consent the claimant gave to be contacted. Avoid advertising that promises outcomes or misrepresents the litigation. Because bar advertising rules, telemarketing law, and litigation criteria all change, verify current requirements with qualified counsel before launching or scaling a campaign, and do not treat marketing screening as a substitute for a lawyer's case evaluation.

How AIM Helps

AIM is a lead exchange operating across three major industry groups, including legal, connecting firms to vetted publishers. Through four premium lead products, mass tort campaigns can combine exclusive form-fill leads captured against your screening fields, qualified inbound calls from claimants responding to campaign ads, warm transfers where a publisher confirms core eligibility before connecting the caller live, and scheduled appointments that pace your intake team. With millions of leads generated and 50,000+ calls processed monthly, AIM supports the consent documentation and quality signals that keep a mass tort program defensible and efficient.

Closing Takeaway

Mass tort lead generation rewards precision. Define written screening criteria for each tort, separate hard disqualifiers from soft signals, and never advance a lead that fails a core requirement. Then back that screening with an intake team ready to answer fast and sign qualified claimants before a competitor does. Track cost per signed retainer, keep your documentation clean, and confirm the current criteria and rules with counsel as litigation evolves.

This article provides educational information only and is not legal advice. Consult qualified counsel about your specific obligations and any active litigation criteria.